Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Neurocrine Bio. (NBIX) PT Lowered to $105 at Cowen
February 6, 2019 7:54 AM ESTCowen analyst Phil Nadeau lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $115.00) while maintaining a Outperform rating.
The analyst commented, "NBIX reported Q4 Ingrezza sales of $130.3MM, consistent with its January pre-announcement. Results from NBI-74788's Ph. IIa in CAH... More
Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c
February 5, 2019 4:02 PM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.19, $0.02 better than the analyst estimate of $0.17. Revenue for the quarter came in at $131.5 million versus the consensus estimate of $129.85 million.
GUIDANCE:
Revenue milestones under the AbbVie agreement for 2019 are expected... More
